Please ensure Javascript is enabled for purposes of website accessibility

Why InterMune Inc. Shares Exploded Higher By More Than 170%

By Sean Williams - Feb 25, 2014 at 1:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

InterMune shares soared after the company released positive late-stage trial data. Should investors jump on this runaway train or stay as far away from the tracks as possible?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of InterMune (ITMN.DL), a biopharmaceutical company primarily focused on pulmonary and fibrotic diseases, skyrocketed by as much as 174% after a report of positive phase 3 results from its ASCEND trial involving pirfenidone (known as Esbriet in Europe) in idiopathic pulmonary fibrosis, or IPF.

So what: According to InterMune's trial results, pirfenidone met both its primary and secondary endpoints in the study. As InterMune noted, a 10% decline in forced vital capacity, or FVC, in an IPF patient is considered clinically meaningful. Just 16.5% of patients taking pirfenidone after 52 weeks had a 10% decline in FVC, or death, compared to 31.8% in the placebo group, demonstrating a nearly 48% reduction over the control arm for the pirfenidone intent-to-treat group. In terms of secondary endpoints, pirfendione "reduced by 27.5% the proportion of patients who experienced a decline in the [six-minute-walking-distance test] of 50 meters of greater." This is important as the test is a measure of exercise tolerance since the treatment was initiated. Overall, pirfenidone reduced the risk of death or disease progression by 43% relative to the control arm. InterMune plans to resubmit its drug for FDA approval in the third quarter.

Now what: Considering that pirfenidone received a complete FDA response letter rejection in 2010, it's surprising to see how strong the data was today. Obviously, nothing is a sure thing when it comes to the FDA, but the primary and secondary endpoint data looks pretty convincing regarding an eventual approval. Still, even with few IPF treatment pathways available, RBC Capital analyst Michael Yee pegged its peak sales at just $300 million to $500 million. With a market valuation of more than $3 billion at the time of writing, and generally weak sales of Esbriet in currently approved European countries, I believe investors may be wise to rethink their optimism.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

InterMune, Inc. Stock Quote
InterMune, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.